Cited 1 time in webofscience Cited 0 time in scopus

The level of autoantibodies targeting eukaryote translation elongation factor 1 Alpha1 and ubiquitin-conjugating enzyme 2L3 in nondiabetic young adults

The level of autoantibodies targeting eukaryote translation elongation factor 1 Alpha1 and ubiquitin-conjugating enzyme 2L3 in nondiabetic young adults
Kim, Eun Hee G.Kwak, Soo HeonHwang, Dae HeeYi, Eu Gene C.Park, Kyong SooKoo, Bo KyungKim, Kristine M.
DGIST Authors
Hwang, Dae Hee
Issue Date
Diabetes and Metabolism Journal, 40(2), 154-160
Article Type
AdultAge DistributionAgedAntibody DetectionAntigenic VariationAutoantibodiesAutoantibodyAutoimmune DiseaseControlled StudyDiabetes Mellitus, Type 1Enzyme Linked Immunosorbent AssayEukaryote Translation Elongation Factor 1 Alpha 1 AutoantibodyFemaleGlutamate Decarboxylase AntibodyGlycosylated HemoglobinHumanInitiation Factor 1AInitiation Factor 1A AutoantibodyInsulin Dependent Diabetes MellitusMajor Clinical StudyMaleOnset AgePrevalenceProtein MicroarrayUbiquitin-Conjugating Enzyme 2L3 AutoantibodyUbiquitin Conjugating EnzymeUbiquitin Conjugating Enzyme 2L3Ubiquitin Conjugating Enzyme 2L3 AutoantibodyUnclassified DrugYoung Adult
Background: The prevalence of novel type 1 diabetes mellitus (T1DM) antibodies targeting eukaryote translation elongation factor 1 alpha 1 autoantibody (EEF1A1-AAb) and ubiquitin-conjugating enzyme 2L3 autoantibody (UBE2L3-AAb) has been shown to be negatively correlated with age in T1DM subjects. Therefore, we aimed to investigate whether age affects the levels of these two antibodies in nondiabetic subjects. Methods: EEF1A1-AAb and UBE2L3-AAb levels in nondiabetic control subjects (n=150) and T1DM subjects (n=101) in various ranges of age (18 to 69 years) were measured using an enzyme-linked immunosorbent assay. The cutoffpoint for the presence of each autoantibody was determined based on control subjects using the formula: [mean absorbance+3×standard deviation]. Results: In nondiabetic subjects, there were no significant correlations between age and EEF1A1-AAb and UBE2L3-AAb levels. However, there was wide variation in EEF1A1-AAb and UBE2L3-AAb levels among control subjects < 40 years old; the prevalence of both EEF1A1-AAb and UBE2L3-AAb in these subjects was 4.4%. When using cutoffpoints determined from the control subjects < 40 years old, the prevalence of both autoantibodies in T1DM subjects was decreased (EEFA1-AAb, 15.8% to 8.9%; UBE2L3-AAb, 10.9% to 7.9%) when compared to the prevalence using the cutoffderived from the totals for control subjects. Conclusion: There was no association between age and EEF1A1-AAb or UBE2L3-AAb levels in nondiabetic subjects. However, the wide variation in EEF1A1-AAb and UBE2L3-AAb levels apparent among the control subjects < 40 years old should be taken into consideration when determining the cutoffreference range for the diagnosis of T1DM. © 2016 Korean Diabetes Association.
Korean Diabetes Association
Related Researcher
  • Author Hwang, Daehee Systems Biology and Medicine Lab
  • Research Interests Multilayered spatiotemporal networks; Regulatory motifs or pathways; Metabolite-protein networks; Network stochasticity; Proteomics and informatics
There are no files associated with this item.
Department of New BiologySystems Biology and Medicine Lab1. Journal Articles

qrcode mendeley

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.